Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.


TSXV:NGEN - Post by User

Post by stargazer1on Dec 26, 2023 4:12pm
253 Views
Post# 35800634

Moving up PARABOLICALLY. LOOK AT THE CHART + NEWS RELEASES

Moving up PARABOLICALLY. LOOK AT THE CHART + NEWS RELEASESNo press release for almost two months, but their press releases have been VERY POSITIVE. Prior to their tenacious research and pharmacuetical examination, NO ONE HAD ANY WAY OF REVERSING SPINAL, OR BRAIN (STROKE ETC.) INJURIES. 

They are the ONLY COMPANY THAT HAS THAT CAPABILITY. Most scientists and physicians were skeptical, BUT THEY ARE COMING AROUND TO BELIEVING IN THE COMPANY'S MEDICATION.

THIS COULD BE A BLOCKBUSTER AND WITH THE WAY THE STOCK IS GOING PARABOLIC, WE MAY BE GETTING READY FOR A BIG PRESS RELEASE.

I've bought more shares and maybe you should consider at least buying some shares.

Stock probably won't really take off until we see if their medication works. But by that time it will be MUCH HIGHER than it is now. So NOW IF THE TIME TO BUY THE SHARES..

Could be a nice Christmas present ... eventually.
<< Previous
Bullboard Posts
Next >>